Carillon Tower Advisors, an investment management firm, has released its Investor Letter for the 4th Quarter 2022 of the Carillon Eagle Small Cap Growth Fund. A copy of the same can be downloaded here. Small-caps posted solid Q4 returns for the first time in 2022. The Russell 2000 Growth Index rose 4.11% and the Russell 2000 Value Index posted a return of 8.39% in the same quarter. Small caps posted disappointing results in 2022. Plus, check out the fund’s top 5 holdings to discover our best picks for 2022.
The Carillon Eagle Small Cap Growth Fund highlighted stocks such as Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its fourth quarter 2022 investor letter. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology company based in San Diego, California. On February 1, 2023, Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock closed at $52.17 per share. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has his one-month return of -3.80%, and the stock has gained his 52.10% of its value over the last 52 weeks. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a market capitalization of $7.054 billion.
The Carillon Eagle Small Cap Growth Fund commented on Halozyme Therapeutics, Inc. (NASDAQ:HALO) in its Fourth Quarter 2022 Investor Letter:
“Hallozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company. The stock continued to perform impressively as investors appreciated the company’s defensive characteristics in the often turbulent biotech industry. The company is also witnessing notable pipeline advancement and commercial success for many of its products. ”
Pressmaster/Shutterstock.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO) isn’t on the list of the 30 most popular hedge funds. According to our database, 21 hedge fund portfolios held his Halozyme Therapeutics, Inc. (NASDAQ:HALO) at the end of the third quarter, up from 21 last quarter.
We covered Halozyme Therapeutics, Inc. (NASDAQ:HALO) in a separate article, sharing Bernzott Capital Advisors’ view of the company. Additionally, for investor letters from hedge funds and other leading investors, visit the Hedge Fund Investor Letters Q4 2022 page.
Recommended articles:
Disclosure: None. This article was originally published on Insider Monkey.
